ArticleMedicine2026
Post-acute symptom persistence following SARS-CoV-2, RSV, and influenza in children: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Persistent symptoms following acute viral respiratory infections are increasingly recognized in children. While post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; long COVID) have been extensively studied, whether comparable post-acute morbidity occurs after other major respiratory viruses and whether clinical patterns differ across pathogens remains incompletely characterized. This retrospective cohort study included children aged 0 to 18 years with reverse transcription polymerase chain reaction-confirmed SARS-CoV-2 (n = 1540), respiratory syncytial virus (RSV; n = 2150), or influenza (n = 2050) infections evaluated between January 2020 and December 2024 at a tertiary university hospital system in Istanbul, Turkey. Persistent symptoms were assessed at clinician-documented follow-up visits 4 to 6 weeks after virological diagnosis. Multivariable logistic regression identified independent predictors for each pathogen. Bonferroni correction was applied for multiple comparisons. Model calibration was assessed using the Hosmer-Lemeshow test, and discriminative ability by the area under the receiver operating characteristic curve. Among 5740 children, persistent symptoms at 4 to 6 weeks were documented in 24.0% (95% confidence interval [CI] = 22.2-25.8) with RSV, 22.0% (95% CI = 19.9-24.1) with SARS-CoV-2, and 21.2% (95% CI = 19.4-23.0) with influenza (P = .086). While overall post-acute prevalence was comparable across the 3 viruses, symptom profiles differed markedly: RSV-related post-acute morbidity was dominated by respiratory and feeding difficulties in young infants; SARS-CoV-2 predominantly produced neurocognitive and systemic complaints in school-aged children; and influenza was characterized by sustained systemic symptoms. Hypoxemia was the strongest predictor for RSV (adjusted odds ratio [aOR] = 2.4, 95% CI = 1.7-3.3), while age >6 years (aOR = 2.1, 95% CI = 1.5-2.9) and hospitalization (aOR = 1.9, 95% CI = 1.4-2.6) were leading predictors for SARS-CoV-2. Age-stratified analyses demonstrated a significant virus × age interaction (P < .001), with the highest prevalence observed after RSV among infants and after SARS-CoV-2 among school-aged children. Hosmer-Lemeshow testing confirmed adequate calibration for all models (all P > .05). Inverse probability weighting sensitivity analysis yielded consistent results. Post-acute symptom persistence following pediatric viral respiratory infections is common and follows virus-specific patterns. Overall post-acute symptom prevalence was comparable across the 3 viruses, but symptom profiles were strikingly virus-specific and age-dependent. This direct comparison of 3 major respiratory viruses demonstrates that post-acute morbidity extends beyond SARS-CoV-2 and varies by pathogen and age. These findings support the development of pathogen-informed follow-up considerations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.